Margaret Tooth Sells 4,000 Shares of Trupanion, Inc. (NASDAQ:TRUP) Stock

Trupanion, Inc. (NASDAQ:TRUP) CEO Margaret Tooth sold 4,000 shares of the stock in a transaction dated Thursday, March 20th. The shares were sold at an average price of $37.17, for a total transaction of $148,680.00. Following the sale, the chief executive officer now directly owns 118,784 shares of the company’s stock, valued at approximately $4,415,201.28. The trade was a 3.26 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Margaret Tooth also recently made the following trade(s):

• On Tuesday, March 4th, Margaret Tooth sold 2,294 shares of Trupanion stock. The stock was sold at an average price of $31.39, for a total transaction of $72,008.66.

Trupanion Stock Performance

Shares of NASDAQ:TRUP traded up $1.61 on Monday, hitting $38.61. 457,442 shares of the company were exchanged, compared to its average volume of 639,547. The firm has a market capitalization of $1.64 billion, a P/E ratio of -167.87, a price-to-earnings-growth ratio of 6.02 and a beta of 1.70. The company has a current ratio of 1.71, a quick ratio of 1.66 and a debt-to-equity ratio of 0.39. Trupanion, Inc. has a 1-year low of $19.69 and a 1-year high of $57.90. The stock’s 50 day moving average price is $41.64 and its 200 day moving average price is $46.74.

Trupanion (NASDAQ:TRUP) last issued its quarterly earnings results on Wednesday, February 19th. The financial services provider reported $0.04 EPS for the quarter, missing analysts’ consensus estimates of $0.06 by ($0.02). The firm had revenue of $337.31 million for the quarter, compared to analyst estimates of $335.41 million. Trupanion had a negative return on equity of 3.08% and a negative net margin of 0.75%. Sell-side analysts predict that Trupanion, Inc. will post 0.13 EPS for the current year.

Analysts Set New Price Targets

Several brokerages have weighed in on TRUP. Piper Sandler lowered their target price on shares of Trupanion from $57.00 to $52.00 and set an “overweight” rating for the company in a research note on Thursday, February 20th. Stifel Nicolaus dropped their target price on Trupanion from $44.00 to $41.00 and set a “hold” rating on the stock in a research note on Thursday, February 20th. Two analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $46.60.

Institutional Investors Weigh In On Trupanion

A number of large investors have recently bought and sold shares of the company. FMR LLC boosted its holdings in shares of Trupanion by 55,963.7% in the 3rd quarter. FMR LLC now owns 1,172,293 shares of the financial services provider’s stock valued at $49,213,000 after acquiring an additional 1,170,202 shares during the last quarter. Amundi lifted its position in Trupanion by 193.2% during the fourth quarter. Amundi now owns 16,828 shares of the financial services provider’s stock valued at $784,000 after purchasing an additional 11,088 shares during the period. Barclays PLC boosted its holdings in Trupanion by 259.2% in the third quarter. Barclays PLC now owns 65,498 shares of the financial services provider’s stock valued at $2,750,000 after purchasing an additional 47,262 shares during the last quarter. Wealthfront Advisers LLC acquired a new stake in Trupanion during the 4th quarter worth about $845,000. Finally, Proficio Capital Partners LLC acquired a new stake in Trupanion during the 4th quarter worth about $976,000.

Trupanion Company Profile

Trupanion, Inc, together with its subsidiaries, provides medical insurance for cats and dogs on a monthly subscription basis in the United States, Canada, Continental Europe, and Australia. The company operates in two segments, Subscription Business and Other Business. It serves pet owners and veterinarians.